2010;115:453-74. Blood. 21. Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets of acute myeloid leukemia.
NLM Biol Blood Marrow Transplant. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. [12] This classification uses the molecular markers to subdivide the intermediate-risk AML into a more favorable Intermediate-I and a less favorable Intermediate-II category. Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis. Prognostic factors in acute myeloid leukemia (AML) may be subdivided into those related to patient characteristics and general health condition, and those related to characteristics of the tumor. 2011;365:725-33. Additionally, non-myeloablative and reduced-intensity conditioning regimens are increasingly making HSCT an option for older patients and those with comorbid conditions, although further studies are necessary to demonstrate a survival advantage of HSCT over chemotherapy for fit but older patients with high-risk AML. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Dohner H, Estey EH, Amadori S, et al.
32. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. 2012;53:110-7. Cornelissen JJ, Breems D, van Putten WL, et al. This site needs JavaScript to work properly. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Cytogenetically normal acute myeloid leukemia (CN-AML) is one form of a cancer of the blood-forming tissue (bone marrow) called acute myeloid leukemia. 6. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Systematic evaluation for an increasing number of nonrandom mutations in AML has allowed better stratification of AMLs with normal cytogenetics (CN-AML), which represent a large proportion (almost 50%) of newly diagnosed cases.
1992;10:1103-11. Cytogenetics, age, and performance status have long determined prognosis and therapy. Get the latest public health information from CDC: https://www.coronavirus.gov.
15. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. 2010;28:556-61. A recent SWOG analysis found that the 4-year survival for patients with complex cytogenetics but without an MK was 13%, but for those with an MK it was only 3%. Data from single centers and transplant registries show that outcomes after transplants from HLA-matched unrelated donors are similar to those from matched siblings. Fang M, Storer B, Estey E, et al.
J Clin Oncol.
USA.gov.
29. J Pediatr Hematol Oncol.
USA.gov. Their treatment options are quite limited and unproven. 31. Get the latest research from NIH: https://www.nih.gov/coronavirus. HHS Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. Orozco and Appelbaum offer a helpful overview of cytogenetic risk classification schemes developed over a period of almost 2 decades by large collaborative groups: the Southwest Oncology Group (SWOG), the Medical Research Council (MRC), and Cancer and Leukemia Group B (CALGB). 2010;116:1839-48. Sci Rep. 2017 Aug 25;7(1):9509. doi: 10.1038/s41598-017-10368-0. 33. [29] Therefore, it may soon be possible to offer transplantation to almost all young patients with high-risk AML who achieve a CR. Grimwade D, Walker H, Harrison G, et al. [30,31], Many older patients with complex-karyotype, MK, and other high-risk–karyotype AMLs, however, are not candidates for either HSCT or intensive chemotherapy. Best Pract Res Clin Haematol. Author information: (1)Division of Hematology and Oncology and the Comprehensive Cancer Center, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Room 1248B, Columbus, OH, 43210-1228, USA.
[17-21] In contrast, improved outcomes following allogeneic HSCT have been clearly documented for younger adults with unfavorable cytogenetics, and more recently, for patients with MK-AML. Clinical significance of cytogenetics in acute myeloid leukemia.
2010;24:1276-82.
Regarding the biology and molecular pathogenesis of unfavorable-risk AML, the association of a complex karyotype with poor prognosis comes as no surprise. Brunstein CG, Gutman JA, Weisdorf DJ, et al.
Mrozek K, Heerema NA, Bloomfield CD. Deng G, Lane C, Kornblau S, Goodacre A, Snell V, Andreeff M, Deisseroth AB. Cytogenetic abnormalities in de novo acute myeloid leukemia in adults: relation to morphology, age, sex and ethnicity - a single center study from Singapore. The separation of homogeneous classes allows us to distinguish pronostic parameters and to identify groups of patients sensitive to drugs or to … 2011;364:1027-36.
Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system.
Cancer. Blood. J Clin Oncol. Armand P, Kim HT, DeAngelo DJ, Ho VT, Cutler CS, Stone RM, Ritz J, Alyea EP, Antin JH, Soiffer RJ. 2015 Apr 20;7(1):e2015033. Blood.
eCollection 2015. 12. Leukemia. 11. 8. HHS 1992;79:313-9.
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
Blood.
25. Prognostic factors in acute myeloid leukemia (AML) may be subdivided into those related to patient characteristics and general health condition, and those related to characteristics of the tumor. 5. In cancer cytogenetics, karyotype complexity has traditionally been considered as a sign of clonal evolution and high mutation load, particularly in the presence of multiple related abnormal clones.
3. Similarly puzzling is the recently described category of AML with MK, and its reportedly dismal prognosis.
Clinical trials of novel therapeutics should be recommended. Rossi G, Pelizzari AM, Bellotti D, Tonelli M, Barlati S. Leukemia. 20. 2004;83(Suppl 1):S106-7.
In this review the common cytogenetic abnormalities seen in AML with reference to associations with the French-American-British (FAB) classification, their possible prognostic significance and their associated molecular biology are summarized.